Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Current Liabilities (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Total Current Liabilities readings, the most recent being $323.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 74.44% year-over-year to $323.6 million, compared with a TTM value of $323.6 million through Dec 2025, up 74.44%, and an annual FY2025 reading of $323.6 million, up 74.44% over the prior year.
  • Total Current Liabilities hit $323.6 million in Q4 2025 for Apellis Pharmaceuticals, up from $279.5 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $323.6 million in Q4 2025, with the low at $83.7 million in Q1 2021.
  • Median Total Current Liabilities over the past 5 years was $172.0 million (2023), compared with a mean of $174.6 million.
  • The sharpest move saw Total Current Liabilities skyrocketed 172.09% in 2021, then fell 25.08% in 2024.
  • Year by year, Total Current Liabilities stood at $131.8 million in 2021, then rose by 27.12% to $167.6 million in 2022, then soared by 47.72% to $247.6 million in 2023, then decreased by 25.08% to $185.5 million in 2024, then surged by 74.44% to $323.6 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $323.6 million, $279.5 million, and $200.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.